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Abstract: Breast cancer related lymphedema (BCRL) is frequent but strategies for an individualized
risk assessment are lacking. We aimed to define whether tumor-specific pathological features, coupled
with clinical and therapeutic data, could help identify patients at risk. Data from 368 patients
with node-positive breast cancers were retrospectively collected, including 75 patients with BCRL
(0.4–25.6 years follow-up). BCRL was assessed during the standard follow-up oncology visits using
the circumferential measurement. Clinicopathologic and therapeutic factors associated with BCRL
were integrated into a Cox proportional hazards regression model. Lymphovascular invasion (LVI)
was more common in BCRL patients (n = 33, 44% vs. n = 85, 29%, p = 0.01), akin extra nodal
extension (ENE) of the metastasis (n = 57, 76% vs. n = 180, 61%, p = 0.02). Sentinel lymph node
excision without axillary dissection and extra-axillary radiotherapy were BCRL-unrelated. A higher
number of BCRL-positive patients were treated with taxane-based chemotherapy with or without
trastuzumab, compared to BCRL-negative patients (p < 0.01). Treatment with trastuzumab and/or
taxanes, adjusted for systemic infections, laterality, therapy, and pathological features (i.e., LVI and
ENE), had a significant impact in BCRL-free survival (p < 0.01). This work offers new insights on
BCRL risk stratification, where the integration of clinical, therapeutic, and tumor-specific pathological
data suggests a possible role of anti-human epidermal growth factor receptor 2 (HER2) therapy in
BCRL pathogenesis.
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1. Background
Treatment of breast cancer has progressed extraordinarily with the introduction of more and more
personalized therapies [1]. However, the improvement in survival observed in recent decades led to
an increased incidence of long-term complications related to the treatments [2–5]. Among them, breast
cancer related lymphedema (BCRL) is one of the most frequent issues in breast cancer survivors treated
with surgery with or without radiotherapy, and has tremendous implications on women’s quality
of life and on sanitary costs [6,7]. This condition is due to an iatrogenic impairment in the transport
capacity of the local lymphatic system after surgery and radiotherapy, which leads to the interstitial
accumulation of lymph fluid in the upper limb [8]. BCRL has a progressive clinical course, usually
showing suboptimal response to surgical, physical, and medical therapies [9]. There are several lines of
evidence to suggest that the early detection of BCRL is cornerstone to allow for an effective treatment.
However, the preventive options available to date are scarce. As a consequence, complete remission in
these patients is seldom accomplished [7].
All patients subjected to axillary procedures (e.g., en bloc dissection, sentinel lymph node,
and irradiation) should be considered at risk for BCRL [6,10–13]. The number of lymph nodes excised
plays a crucial role, not only for mechanical reasons but probably also because of the increased use of
radiotherapy in patients with numerous metastatic nodes [10,13–15]. Furthermore, patients subjected to
radical mastectomy show a higher frequency of BCRL compared to those treated with breast-conserving
surgery (i.e., quadrantectomy, lumpectomy) [16,17]. Some authors have also hypothesized the role of
taxane-based chemotherapy in BCRL pathogenesis, but only in women subjected to axillary lymph
nodes dissection (ALND) [18–21]. Other risk factors include high body mass index (BMI), smoking,
and alcoholism, confirming the role of non-communicable diseases in long-term complications in
breast cancer survivors [22]. There is recent evidence that tumor-specific biological features, such as
peritumoral lymphovascular invasion (LVI) and extranodal extension (ENE), are involved in BCRL
pathogenesis [14]. Regrettably, all these variables are not integrated in BCRL clinical workup.
Realizing new strategies for assessing the individual risk of lymphedema in breast cancer
survivors is a crucial clinical need. Our working hypothesis was that the integration of tumor-specific
biological features with patients’ clinical and therapeutic data could improve BCRL risk stratification.
Using an integrative risk-assessment platform, we sought to characterize new risk factors for BCRL.
2. Materials and Methods
2.1. Study Cohort
This observational study included a retrospective series of women with node-positive (pN ≥ 1)
breast cancers diagnosed from January 1998 to September 2018 at Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Milan, Italy. All patients underwent breast surgery with standard
adjuvant treatment (medical and radiotherapy) that was based on risk stratification. Outcome data
were collected, and only patients with uniformly recorded BCRL status and detailed information on
the adjuvant therapeutic protocols employed were included. Likely or documented syndromic tumors,
pregnancy-associated breast cancers, or those treated in the neoadjuvant setting were excluded for this
study. Patients were anonymized prior to data collection and analysis. The study was approved by the
local Independent Ethics Committee under protocol number #620_2018bis.
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2.2. BCRL Assessment
For all patients, BCRL was assessed during the standard follow-up oncology visits using the
circumferential method [14,23]. In the presence of macroscopic evidence and/or patients complains
of BCRL (e.g., swelling, heaviness, pain, aching, limb fatigue, impaired mobility), the limb volume was
calculated considering the arm either as a single segment or as the sum of the truncated cone volumes
represented by the multiple segments. For this analysis, sequential circumferential measurements were
taken every 5-cm interval, distally and proximally to the crease of the elbow, using a tape and compared to
the contralateral arm. In the presence of an interlimb difference≥2 cm at any single location or≥200 mL,
BCRL was confirmed and annotated as a dichotomous variable (i.e., BCRL+ and BCRL−) [24].
2.3. Histological Review
Tumor classification, grading, and pathological staging were re-performed for all cases following
the latest recommendations [25] and guidelines [26,27]. All cases were independently reviewed by
three pathologists with a particular interest in breast pathology (Gianluca Lopez, Letterio Runza,
and Nicola Fusco). Discordant results were resolved collegially. LVI and ENE were assessed following
the College of American Pathologists 2017 Protocol for the examination of specimens from patients
with invasive carcinoma of the breast (v.4.0.0.0, available at https://www.cap.org/cancerprotocols),
as previously described [14,28–34].
2.4. Statistical Analyses
All the statistical analyses were performed using the SAS 9.4 software (SAS Institute, Cary, NC,
USA). Categorical variables were annotated as absolute numbers with the corresponding percentage.
To summarize the continuous variables, the mean and standard deviation (SD) or median and
quartiles (Q1, Q3) were used. The Shapiro-Wilk test was employed to analyze the normal distributions.
Associations between BCRL, demographic and clinical information, pathologic and molecular features
of the tumors, and treatment data were performed using the Fisher’s exact test, chi-squared test,
or Wilcoxon rank-sum, according to the type of variables. Subsequently, Cox’s proportional hazard
regression models were used for multivariate analyses, and covariates were selected using the
purposeful method [14,35]. The proportional hazard assumption was verified considering Schoenfeld’s
residuals of each covariate [36]. The linearity assumption for quantitative variables was evaluated on
the basis of the quartiles [37]. For each predictor, the hazard ratio (HR) and 95% confidence intervals
(CI) were provided. Survival curves were built according to the Kaplan-Meier method and compared
using the Log-Rank test, as previously described [38]. All statistical tests were two-tailed; only p-values
of less than 0.05 were considered statistically significant.
3. Results
A total of 368 women (age, 26–88 years; median, 58 years) with pN≥ 1 breast cancer were included
in this study (follow-up time, 0.4–25 years; median 6.2 years). Among them, 75 (20%) patients were
BCRL-positive and 293 (80%) were BCRL-negative. The median time of BCRL onset was 1.6 years (range
0.2–8.2 years). The demographic data and general characteristics of the study group are listed in Table 1.
Table 1. Demographic data and general characteristics of the patients included in the study. BCRL,
breast cancer related lymphedema; SD, standard deviation; BMI, body mass index.
BCRL+ (n = 75) BCRL− (n = 293) p-Value
Age at diagnosis, years, mean ± SD 57.9 ± 13.1 59.5 ± 12.9 0.3879
Menopause, n (%)
Peri- 1 (1.4) 9 (3.1)
0.6845Post- 49 (67.1) 195 (67.7)
Pre- 23 (31.5) 84 (29.1)
Smoking status, current smoker, n (%) 8 (10.7) 29 (9.9) 0.8433
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Table 1. Cont.
BCRL+ (n = 75) BCRL− (n = 293) p-Value
BMI, mean ± SD 27.0 ± 5.6 26.9 ± 5.4 0.9572
Obesity, BMI ≥ 30 kg/m2 n (%) 16 (21.3) 78 (26.6) 0.3488
Diabetes mellitus, n (%) 7 (9.3) 19 (6.5) 0.3903
Cardiovascular diseases, n (%) 25 (33.3) 83 (28.3) 0.3956
Systemic infections, n (%) 10 (13.3) 18 (6.1) 0.0361
Blood disorders, n (%) 6 (8.0) 25 (8.5) 0.8822
Bone and joints diseases, n (%) 7 (9.3) 32 (10.9) 0.6901
Dyslipidemia, n (%) 5 (6.7) 44 (15.0) 0.0575
Gastrointestinal diseases, n (%) 14 (18.7) 51 (17.4) 0.7984
Diseases of the urinary tract, n (%) 4 (5.3) 16 (5.5) 1.0000
Diseases of the reproductive tract, n (%) 12 (16.0) 49 (16.7) 0.8805
Central nervous system diseases, n (%) 1 (1.3) 25 (8.5) 0.0299
Other neoplasms, n (%) 10 (13.3) 42 (14.3) 0.8242
3.1. Tumor-Specific Biological Features Associated with BCRL
Lymphedema was observed more frequently in patients with cancers of the right breast (n = 48, 64%,
p = 0.02), whereas in the BCRL-negative population the tumors were equally distributed among the left
(n = 151, 51%) and right (n = 142, 49%) sides. In both cohorts the most frequently diagnosed histological
type was the invasive ductal carcinoma. No statistically significant differences among BCRL-positive and
BCRL-negative tumors were observed in terms of tumor stage, histological grade, proliferation index,
and hormone receptor status. LVI at the periphery of the primary tumor was detected in 44% (n = 33) of
BCRL patients, while only 29% (n = 85) of the BCRL-negative population showed this feature (p = 0.01).
The prevalence of ENE of the metastasis was significantly higher (p = 0.02) in BCRL-positive (n = 57, 76%)
than in BCRL-negative patients (n = 180, 61%). These observations confirm that intrinsic biological features
of both the tumor and metastasis are bona fide biomarkers of BCRL occurrence. All clinicopathologic
features are summarized in Supplementary Table S1.
3.2. The Type of Axillary Surgical Dissection But Not the Type of Breast Surgery Impacts on BCRL
The condition of BCRL was restricted to the patients subjected to ALND, as those who underwent
only sentinel lymph node procedure (n = 19, 7%) were all BCRL-negative (p = 0.02). Breast conservative
surgery was the most widely adopted surgical approach both in BCRL-positive (n = 47, 63%) and
BCRL-negative (n = 177, 60%) patients, as shown in Table 2. No statistically significant correlation
was observed between the type of breast surgery and BCRL. These data provide circumstantial
evidence that BCRL is likely not to be a direct consequence of the breast surgery and that non-invasive
procedures in the axilla are not able alone to trigger this condition.
Table 2. Therapeutic protocols of the patients included in the study.
BCRL+ (n = 75) BCRL− (n = 293) p-Value
Breast surgery, n (%)
Conservative 47 (62.7) 177 (60.4)
0.7208Mastectomy 28 (37.3) 116 (39.6)
Axillary surgery, n (%)
En bloc dissection 75 (100.0) 274 (93.5)
0.0178Sentinel lymph node 0 (0.0) 19 (6.5)
Radiotherapy, n (%)
No
WBI
WBI + SCF
SCF + CW
21 (28.0)
36 (48.0)
7 (9.3)
11 (14.7)
78 (26.6)
153 (52.2)
16 (5.5)
46 (15.7)
0.6318
Chemotherapy, n (%)
No
Taxanes
Other protocols
22 (29.3)
45 (60.0)
8 (10.7)
153 (52.2)
110 (37.5)
30 (10.2)
0.0010
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Table 2. Cont.
BCRL+ (n = 75) BCRL− (n = 293) p-Value
Hormone therapy, n (%)
No
SERM
Aromatase inhibitors
SERM + Aromatase inhibitors
SERM + LHRH agonists
14 (18.7)
6 (8.0)
34 (45.3)
11 (14.7)
10 (13.3)
36 (12.3)
43 (14.7)
135 (46.1)
44 (15.0)
35 (12.0)
0.4206
Duration of the intake (days), median (Q1, Q3)
SERM
Aromatase inhibitors
LHRH agonists
301 (252; 349)
1586 (1095; 1827)
1200 (731; 1358)
300 (216; 371)
1544 (967; 1836)
989 (708; 1765)
1.0000
0.8658
0.9343
Trastuzumab, n (%) 11 (14.7) 19 (6.5) 0.0209
BCRL+ (n = 75) BCRL− (n = 293) p-Value
Breast surgery, n (%)
Conservative 47 (62.7) 177 (60.4)
0.7208Mastectomy 28 (37.3) 116 (39.6)
Axillary surgery, n (%)
En bloc dissection 75 (100.0) 274 (93.5)
0.0178Sentinel lymph node 0 (0.0) 19 (6.5)
Radiotherapy, n (%)
No
WBI
WBI + SCF
SCF + CW
21 (28.0)
36 (48.0)
7 (9.3)
11 (14.7)
78 (26.6)
153 (52.2)
16 (5.5)
46 (15.7)
0.6318
Chemotherapy, n (%)
No
Taxanes
Other protocols
22 (29.3)
45 (60.0)
8 (10.7)
153 (52.2)
110 (37.5)
30 (10.2)
0.0010
Hormone therapy, n (%)
No
SERM
Aromatase inhibitors
SERM + Aromatase inhibitors
SERM + LHRH agonists
14 (18.7)
6 (8.0)
34 (45.3)
11 (14.7)
10 (13.3)
36 (12.3)
43 (14.7)
135 (46.1)
44 (15.0)
35 (12.0)
0.4206
Duration of the intake (days), median (Q1, Q3)
SERM
Aromatase inhibitors
LHRH agonists
301 (252; 349)
1586 (1095; 1827)
1200 (731; 1358)
300 (216; 371)
1544 (967; 1836)
989 (708; 1765)
1.0000
0.8658
0.9343
Trastuzumab, n (%) 11 (14.7) 19 (6.5) 0.0209
BCRL, breast cancer related lymphedema; WBI, whole breast irradiation; SCF, supraclavicular fossa; CW, chest wall;
SERM, selective estrogen receptor modulator (Tamoxifen); LHRH, luteinizing hormone releasing hormone agonist;
Q1, quartile 1; Q3, quartile 3.
3.3. Extra-Axillary Radiotherapy Does Not Increase the Risk of BCRL
Whole breast irradiation (WBI) was the most frequently adopted radiotherapy protocol among
both BCRL-positive (n = 43, 57%) and BCRL-negative (n = 169, 58%) patients, including 7 (9%) and
16 (6%) cases, respectively, subjected to additional irradiation of the supraclavicular fossa (Table 2).
WBI was performed after surgery as one treatment per day, five days a week, for five to seven weeks.
A supplemental boost dose has been variably included at the end of the regimen. In our cohort,
all patients treated with mastectomy and radical lymphadenectomy showing ≥4 metastatic lymph
nodes received radiotherapy on both the supraclavicular fossa and the chest wall (n = 57, 16%). None of
the patients included in this study received axillary irradiation, while 21 (28%) BCRL-positive and 78
(27%) BCRL-negative patients were radiotherapy-naïve. Overall, extra-axillary radiation therapy was
not associated with BCRL (Table 2).
3.4. Taxanes-Based Chemotherapy Is Associated with BCRL Occurrence
Fisher’s exact test showed a strong association between adjuvant chemotherapy and BCRL
(p < 0.01), as displayed in Table 2. Taken together, a higher prevalence of chemo-treated patients was
observed in the BCRL-positive cohort (n = 53, 71%), compared to the BCRL-negative (n = 140, 48%),
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as shown in Table 2. In particular, 45 (60%) BCRL patients were treated with taxane-based protocols
(e.g., epirubicin and cyclophosphamide followed by docetaxel), in contrast to BCRL-negative patients
(n = 110, 38%). The higher incidence of BCRL was not observed in patients treated with other (i.e.,
taxanes-free) protocols (Table 2). These results were corroborated by the observation that more than
half of unaffected subjects (n = 153, 52%) received neither taxanes nor other chemotherapy protocols.
Log-rank test demonstrated that taxanes, but not other chemotherapeutics, had a significant impact
on BCRL-free survival (p < 0.01), as represented in Figure 1. The association between chemotherapy
and BCRL was further evaluated using a Cox proportional hazard model (Table 3). This analysis
showed that taxanes administration exposes breast cancer patients to a doubled risk of developing
lymphedema (HR = 2.24, 95% CI (1.26–3.98)), compared to other protocols (Table 3). No significant
correlations were observed between BCRL and hormone therapy, regardless of both the therapeutic
protocol and duration of the treatment (Table 2).
Table 3. Clinicopathologic factors associated with the development of breast cancer related
lymphedema (Cox proportional hazard model).
HR 95% CI p-Value
Systemic infections 1.88 0.95–3.71 0.0703
Chemotherapy, no 1.00
Taxanes
Other protocols
2.24
1.21
1.26–3.98
0.50–2.94
0.0060
0.6684
Trastuzumab 2.70 1.31–5.55 0.0071
No radiotherapy, no 1.00
WBI
WBI + SCF
SCF + CW
0.73
0.71
0.45
0.42–1.28
0.29–1.73
0.20–0.98
0.2678
0.4549
0.0446
Side ENE 0.0144
Right Yes vs. No 3.11 1.45–6.65
Left Yes vs. No 0.76 0.32–1.78
Side LVI 0.0208
Right Yes vs. No 1.09 0.59–2.00
Left Yes vs. No 3.56 1.61–7.87
HR, hazard ratio; CI, confidence interval; WBI, whole breast irradiation; SCF, supraclavicular fossa; CW, chest wall;
ENE, extranodal extension; LVI, lymphovascular invasion.
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Figure 1. Lymphedema-free survival of the patients included in the study according to the type
of chemotherapy. The curves are built according to the by Kaplan-Meier method, p values are the
expression of Log-rank test. The specific risk for a given timeframe is reported on the bottom of each
graph. BCRL, breast cancer related lymphedema; CT, chemotherapy.
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3.5. Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibodies Administration
Increase the Risk of BCRL
The rate of human epidermal growth factor receptor 2 (HER2)-positive carcinomas was higher in
patients with BCRL (n = 11, 15%) than in BCRL-negative (n = 26, 9%), albeit not statistically significant
(Supplementary Table S1). All HER2-positive patients with BCRL, before developing lymphedema,
were treated with the monoclonal antibody trastuzumab (TTZ), while only 19 (73%) women with
HER2-positive tumors (n = 26) in the BCRL-negative group were treated with anti-HER2 therapy.
According to Fisher’s exact test, the association between anti-HER2 targeted therapy and BCRL was
significant, (p = 0.02), as shown in Table 3. This association was retained while performing survival
analyses (p < 0.01), as depicted in Figure 2. Despite the small sample size, the significance was
maintained after the inclusion of TTZ therapy in the Cox Proportional Hazard model comprising LVI
and ENE (p = 0.01). This analysis provided evidence that anti-HER2 therapy with TTZ increased the
risk of subsequent BCRL by nearly three times (HR = 2.7, 95% CI (1.31–5.55)). The therapeutic timeline
of BCRL patient treated with anti-HER2 drugs is outlined in Figure 3.
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Figure 3. Schematic r presentatio of the therapeutic tory of BCRL patient. The timeline depicts
the months after surgery, as reported on the top; patients are reported as rows, according to their
ID on the left; the type of therapy is color-coded on the basis of the legend on the bottom. The first
BCRL diagnosis is highlighted as a red star in the timeline. CHT, chemotherapy (no taxanes); Tax-CHT,
taxane-based chemotherapy; BCRL, breast cancer related lymphedema.
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4. Discussion
BCRL occurs in a remarkable proportion of breast cancer survivors, thus involving hundreds of
thousands of women worldwide, with a significant impact on social and sanitary costs [7]. Despite risk
factors have been identified, patients risk stratification is not performed to date. As a result, BCRL is
treated at its occurrence, in contrast with the modern principles of preventive medicine. Regrettably,
BCRL is poorly responsive to surgical, physical, and medical therapies. Therefore, the currently
available preventive strategies, if applied at an individualized level, could improve patients’ outcome
and sanitary interventions. We have hypothesized that the integration of multiple clinical information
with tumor-specific pathological information would be germane for improving the currently available
guidelines to define individuals at risk. Here, we performed a comprehensive analysis of a large series
of surgically-treated pN ≥ 1 breast cancers with long-term follow-up and found that extra-axillary
radiotherapy, sentinel lymph node procedure, and extensive surgical procedures on the breast are not
able alone to increase the risk of BCRL. Furthermore, we confirm the strong predictive value of LVI
and ENE for BCRL occurrence and that their evaluation is able to identify new risk factors, such as
TTZ therapy. Finally, we corroborate the notion that, among chemo-treated patients, BCRL occurs
preferentially in the setting of therapy with taxanes.
In our study, we provide new insights on how breast cancer systemic therapy can influence
BCRL-free survival. The potential association of endocrine therapy, chemotherapy and anti-HER2
targeted therapy with lymphedema was evaluated with a comprehensive risk model, encompassing
both treatment-related and pathological indicators. Data of our cohort of patients confirmed the
detrimental impact of adjuvant chemotherapy. In detail, HR significantly increases when patients
are treated with taxanes-based protocols, supporting previous literature findings [20,21]. In initial
stages, lymphedema development is characterized by interstitial fluid retention and accumulation of
protein-rich fluid. This process may be worsened by adjuvant chemotherapy with a mechanism that
closely resembles early pathological changes typical of secondary lymphedema. Indeed, taxanes,
and in particular docetaxel, can lead to an enhancement of interstitial fluid filtration, capillary
protein leakage and subsequently edema [39]. Therefore, adjuvant taxanes-based protocols can
contribute to the initiation and maintenance of BCRL by increasing fluid collection early on after
surgery, when lymphatic drainage is markedly impaired by axillary dissection procedures.
More interestingly, we were able to identify a significant correlation between anti-HER2 therapy
and BCRL. Despite the small sample size of the HER2-positive tumors included in this study,
our data provides previously unavailable evidence that patients who receive TTZ are at higher
risk of postsurgical lymphedema. Given that the adjuvant systemic therapy with TTZ requires the
administration of concurrent chemotherapy, we can hypothesize the additive effect of anti-HER2
monoclonal antibodies to chemotherapeutics. To date, no adverse effects of TTZ on microcirculation
or fluid retention have been described. However, this monoclonal antibody selectively binds HER2,
which is part of human epidermal growth factor receptor family [40]. HER2 overexpression has
been linked to higher levels of vascular endothelial growth factor (VEGF)-C, which is a key player
in lymphatic development, and subsequent increase in lymphangiogenesis [41]. Evidences in vitro
showed that VEGF-C mRNA and protein expression decreased significantly in breast cancer cells
after TTZ, supporting the assumption of a clinically relevant association between HER2 and VEGF-C
levels [42]. Therefore, the blockade of HER2 by monoclonal antibodies, such as TTZ, may on one hand
reduce direct proliferative effects of VEGF-C on tumor cells and on the other hand, for its systemic
effect, diminish lymphangiogenesis in the site of surgery, preventing lymphatic regeneration and thus
promoting lymphedema.
This study has intrinsic limitations. First, its retrospective nature prevented a rigorous and
uniform measurement of the arm volume. Hence, the sensitivity of the circumferential method
has been questioned by many authors, particularly in the presence of arm shape irregularities and
gibbousness [43,44]. Overall, the lack of a baseline measurement of the limb volume prior to the
development of macroscopic BCRL, coupled with the fact that the measurements were not always
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taken at regular intervals, could have led to an underestimation of the real incidence of BCRL in
our population of patients. To overcome potential biases in quantification we chose to annotate
BCRL as a dichotomous variable. However, this study should be considered hypothesis-generating.
Further clinical studies coupled with detailed records of both arm volumes at regular intervals using
cutting-edge tools (i.e., bioimpedance spectroscopy or tissue dielectric constant analysis), information
on weight gain and symptoms of fluid retention (e.g., facial edema) during chemotherapy, and duration
of the specific interventions will be required to allow for BCRL staging, including latent and subclinical
conditions. Second, the relatively small sample size of HER2-positive tumors included in the study
could have limited the clinical impact of our conclusions. It should be noted, however, that our
work provides for the first time in literature evidence on the possible role of trastuzumab in BCRL
pathogenesis. Large-scale studies enriched for HER2-positive breast cancers are warranted to confirm
our observations. Third, we cannot rule out the possibility that the correlation of TTZ treatment in
BCRL onset could be related to a carry-over effect of the combined treatment with taxanes, in particular
considering the different protocols adopted during the long time-frame of patients’ recruitment
(1993–2018). To this end, functional studies exploring the individual role of specific drugs in BCRL
would be needed.
5. Conclusions
Despite these limitations, our work offers novel insights in BCRL risk stratification, where the
integration of demographic, clinical, therapeutic, and tumor-specific pathologic data could represent
a step forward for the prevention, or at least prediction, of long-term complications in breast cancer
survivors. The assessment of LVI and ENE could be beneficial not only for the implementation of
BCRL active surveillance protocols in the setting of trastuzumab therapy, but also for tailoring the
surgical intervention, follow-up, and therapeutic strategy in women with node-positive breast cancer.
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